IDRx Secures $120M for Pivotal KIT Inhibitor Study with Promising Early Data

Funding:
IDRx has raised $120 million in funding to support a pivotal study for its KIT inhibitor, IDRX-42.

Early Data:
The Phase I/Ib StrateGIST 1 study has shown an objective response rate of 43% in patients with KIT-mutant GIST.

Study Details:
The study is enrolling patients with KIT-mutant GIST to receive doses of IDRX-42 ranging from 120 mg once-daily to 600 mg once-daily.

Investors:
The funding round was likely supported by various investors, although specific details on the investors involved in this round are not provided in the sources.

Clinical Significance:
The positive early data and significant funding indicate a promising outlook for IDRX-42 in treating KIT-mutant GIST, a type of gastrointestinal stromal tumor.